Skip to Content

Plantar Fasciitis

Plantar fasciitis is a painful and sometimes debilitating condition caused by the inflammation of the tissue that runs across the bottom of your foot and connects your heel bone to your toes. The pain from plantar fasciitis can become excruciating and chronic that makes work, exercise and ordinary walking challenging and difficult.1

Not an actual patient

In November 2020, Revance announced results from a Phase 2 clinical trial evaluating the company’s investigational drug candidate, DaxibotulinumtoxinA for Injection, for the management of plantar fasciitis. Revance plans to analyze the data further for additional insights, however our primary focus will be on neuromodulator indications, where the market and path to approval are well established.

DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA.

Learn More
1 in 10

Estimated number of people in the U.S. will develop plantar fasciitis in their lifetime.2


Americans experience symptoms of plantar fasciitis at any one time.2

6 Months

Symptoms can last six months or more, sometimes requiring surgery.3

There have been no new FDA-approved pharmacological treatment options for plantar fasciitis. The current treatments for the disorder either provide only temporary relief or are quite invasive. In the hope to provide a potential treatment option for the millions of people who seek relief from this debilitating foot pain, DaxibotulinumtoxinA for Injection was evaluated in a clinical trial for the management of plantar fasciitis. To learn more about the Phase 2 clinical trial, click here.

Beyond plantar fasciitis, Revance is continuing to study DaxibotulinumtoxinA for Injection in other important therapeutic indications with a current focus in muscle movement disorders. 

DaxibotulinumtoxinA for Injection has delivered highly positive Phase 3 results, including strong duration of effect, demonstrating a median duration of 24 weeks in the treatment of glabellar lines and cervical dystonia. Additionally, Revance plans to share Phase 2 trial results for upper limb spasticity in first quarter 2021.


1. Mayo Clinic Web Site. Accessed 8/11/20

2. Schneider H. et al. ACFS Clinical Consenus Statement. Journal of Foot and Ankle Surgery 2017

3. Tehririan MA et al. Plantar Fasciitis. J Res Med Sci. 2012 Aug; 17(8): 799–804

Back to top